



## AMGEN MISSION

To serve patients

## AMGEN KOREA QUICK FACTS

### Leadership

Sangkyung Noh, General Manager

### Staff

148 in Korea (as of June 2021)

### R&D Expense

Approximately \$4.1 billion (as of 2020, Amgen Global Headquarters)

### Products

Repatha® (evolocumab)

Blinicyto® (blinatumomab)

Xgeva® (denosumab)

Evenity® (romosozumab-aqqg)

Kyprolis® (carfilzomib)

Prolia® (denosumab)

### Address/Phone

Amgen Korea 20 FL,  
Ferrum Tower, 19  
Eulji-ro 5-gil, Jung-gu, Seoul  
(82) 2-3434-4800

### Global Headquarters

Thousand Oaks, California

For more information on Amgen Korea, please visit

[WWW.AMGEN.CO.KR](http://WWW.AMGEN.CO.KR)

For more information on Amgen Inc., please visit

[WWW.AMGEN.COM](http://WWW.AMGEN.COM)

## AMGEN KOREA

Amgen, founded in 1980 in Thousand Oaks, California, US has grown to be one of the world's leading biotechnology companies by unlocking the potential of biology into innovative human therapeutics. As a biotechnology leader, Amgen focuses on areas of high unmet medical needs and leverages advanced human genetics to unravel the complexities of disease, develop an innovative pipeline of transformative new medicines, and reach millions of patients around the world.

Amgen opened an affiliate in Korea in November, 2015, to market its innovative bio medicines for Korean patients under the mission of "To Serve Patients" in therapeutic areas of bone disease, cardiovascular, and oncology. Amgen Korea is committed to playing an active role in biotechnology and thereby helping to advance the growth of the local pharmaceutical industry.

## BIOTECH-POWERED TRANSFORMATIVE MEDICINES OFFERING INNOVATIVE CLINICAL BENEFIT FOR LOCAL PATIENTS

Amgen Korea provides transformative medicines powered by its expertise in biotechnology to give alternative treatment options with breakaway potential to local patients suffering from serious illnesses.

So far 6 therapies from Amgen, all powered and enabled by Amgen's expertise in biotechnology, have become available in Korea starting from Kyprolis® (carfilzomib) for multiple myeloma in April 2016, followed by Blincyto® (blinatumomab), Prolia® (denosumab), Xgeva® (denosumab), Repatha® (evolocumab), and Evenity® (romosozumab-aqqg). Patient access to medicines has also been our priority in Korea to ensure more patients are benefitted from our medicines, resulting in key products becoming reimbursable in a short period of time.

On the back of its broad pipeline of new medicines in clinical development, Amgen Korea strives to deliver innovative new medicines to local patients faster in such therapeutic areas as solid tumor and hematologic malignancy.

## AMGEN KOREA HISTORY

### 2015

- Amgen's Korean affiliate opens
- Sangkyung Noh takes office as GM
- MoFDS approves Blincyto®
- MoFDS approves Kyprolis®\*

### 2016

- Blincyto® becomes reimbursable

### 2017

- Repatha® is approved
- Prolia® becomes reimbursable

### 2018

- Creative Science Camp, Amgen's Corporate Responsibility initiative for underprivileged children, is held
- Kyprolis® becomes reimbursable
- Repatha® becomes reimbursable
- Xgeva® becomes reimbursable

### 2019

- Evenity® is approved
- Amgen Korea is selected as Korea Exemplary Workplace by MoEL
- Amgen Korea office moves to Ferrum Tower in Eulji-ro

### 2020

- Evenity® becomes reimbursable
- An MOU with the Seoul Science Center is signed for the Grow up, Bio up campaign
- Amgen Korea is awarded the Seoul Council on Social Welfare Chairman's Certificate of Recognition in celebration of the 3<sup>rd</sup> Social Contribution Week hosted by the City of Seoul and Seoul Council on Social Welfare
- Amgen Korea is presented the Red Cross Membership Merit Honor Award by the Korean Red Cross

### 2021

- An MOU with the Korean Academy of Science and Technology is signed for the Amgen-KAST Biotechnology Award
- An MOU with the Seoul Jung-gu Office and Seoul Community Chest of Korea is signed for the Golden House campaign

*\*Marketing approval as an orphan drug was granted in November 2015 and the orphan drug designation was lifted in March 2017, after which new drug approval was granted*

Amgen Korea Key Products	
Prolia®	Postmenopausal women/men with osteoporosis Bone loss in patients with nonmetastatic prostate/breast cancer Glucocorticoid-induced osteoporosis
Xgeva®	Prevention of skeletal-related events in patients with multiple myeloma and in patients with bone metastases from solid tumors Giant cell tumor of bone
Blincyto®	MRD(+) B-cell Precursor ALL Relapsed or refractory B-cell precursor ALL
Kyprolis®	Relapsed or refractory multiple myeloma
Repatha®	Primary hypercholesterolemia or mixed dyslipidemia Lowering of LDL-C levels in atherosclerotic CV disease to reduce the cardiovascular risk Homozygous familial hypercholesterolemia
Evenity®	Osteoporosis in postmenopausal women/men at high risk of fracture

## GIVING THE SOLUTION AS A BIOTECHNOLOGY LEADER WITH CONTINUOUS INVESTMENT IN R&D

A leading innovator in biotechnology since 1980, Amgen has cultivated and accumulated R&D expertise in multiple treatment modalities – large molecule proteins, small molecules and antibodies – allowing us to choose and capitalize on the best target for attacking disease. Amgen focuses on six therapeutic areas: cardiovascular disease, oncology, bone health, neuroscience, nephrology and inflammation. Amgen is continuously investing in new drug discovery research efforts to further advance our pipeline and clinical asset.

Amgen Korea has been relentless in making an investment in clinical trials in Korea for the past 10 years (as of June 2021) in such diverse areas as cardiovascular disease, oncology, bone disease, neuroscience, nephrology and inflammation. We have had 59 clinical trials with 473 clinical trial sites and 6,381 patients in Korea being involved in the clinical trials led by Amgen. The investment is to demonstrate that our innovative medicines in development can offer clear clinical benefit and value to local patients as well, showcasing our effort to help more local patients be benefitted from our transformative products in line with Amgen's mission of "To Serve Patients". Amgen Korea, as a biotechnology leader, will continue to invest in broad research programs, talent development, and organizational growth to encourage mutual growth with the local healthcare industry equipped with excellent researchers and infrastructure.

## SOCIAL RESPONSIBILITIES FOR MUTUAL GROWTH

Amgen Korea aims for not just business development but shared growth with the society, as evident in our broad Corporate Responsibility initiatives. Our efforts, both internal and external, to improve the local job market by creating exemplary work environment and hiring young job seekers to help ease youth unemployment were acknowledged by the Ministry of Employment and Labor, which named Amgen Korea "2019 Korea Exemplary Workplace". As a leading biotechnology company with proven expertise, Amgen Korea is also an advocate for life science learning for the next generations. The Amgen Korea Science Camp for children from a less privileged background in 2018 was one of our first Corporate Responsibility initiatives for science

education for children and adolescents in Korea, which was followed by the Grow up, Bio up campaign in partnership with the Seoul Science Center from 2020. Additionally, in 2021, we signed an MOU with the Korean Academy of Science and Technology for the Amgen-KAST Biotechnology Award aiming at giving young promising scientific minds in Korea a much-needed leg-up.

In the thick of the COVID-19 pandemic in 2020, Amgen Korea lent a helping hand jointly with Amgen Global to those marginalized by the pandemic, with the Korean Red Cross and Seoul Council on Social Welfare, as part of the public health and livelihood support programs. Our resolve to help the less privileged was appreciated when we were awarded the Seoul Council on Social Welfare Chairman's Certificate of Recognition in celebration of the 3rd Social Contribution Week by the City of Seoul, and the Red Cross Membership Merit Honor Award by the Korean Red Cross. In 2021, an MOU with the Seoul Jung-gu office and Seoul Community Chest of Korea was signed for the Golden House Campaign designed to improve housing conditions for the less privileged and elderly living in Jung-gu district for the prevention of bone fracture, better public health, and living environment. Amgen Korea is committed to introducing more programs and finding opportunities to encourage mutual growth with the local community.